Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

FAIR VALUE (Details)

FAIR VALUE (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Liabilities:
Warrants	$ 1,128,499us-gaap_DerivativeLiabilitiesCurrent	$ 3,359,363us-gaap_DerivativeLiabilitiesCurrent
February 2013 Public Offering Warrants [Member]
Liabilities:
Warrants	1,127,500	3,355,000
Legacy Warrants [Member]
Liabilities:
Warrants	999	4,363
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrants	0	0
Fair Value, Inputs, Level 1 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Warrants	0	0
Fair Value, Inputs, Level 1 [Member] \| Legacy Warrants [Member]
Liabilities:
Warrants	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrants	999	4,363
Fair Value, Inputs, Level 2 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Warrants	0	0
Fair Value, Inputs, Level 2 [Member] \| Legacy Warrants [Member]
Liabilities:
Warrants	999	4,363
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrants	1,127,500	3,355,000
Fair Value, Inputs, Level 3 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Warrants	1,127,500	3,355,000
Fair Value, Inputs, Level 3 [Member] \| Legacy Warrants [Member]
Liabilities:
Warrants	$ 0	$ 0

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References + Details